Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Predictive factors of radiation-induced skin toxicity in breast cancer patients

Authors: Miao-Fen Chen, Wen-Cheng Chen, Chia-Hsuan Lai, Chao-hsiung Hung, Kuo-Chi Liu, Yin-Hsuan Cheng

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

To assess the factors affecting the incidence of radiation-induced dermatitis in breast cancer patients treated with adjuvant 3 D conformal radiotherapy by the analysis of dosimetry and topical treatments.

Methods

Between September 2002 and July 2009, 158 breast cancer patients were treated with adjuvant 3 D conformal radiotherapy after undergoing surgery. Before November 2006, 90 patients were subjected to therapeutic skin care group and topical corticosteroid therapy was used for acute radiation dermatitis. Thereafter, 68 patients received prophylactic topical therapy from the beginning of radiotherapy. The two groups did not differ significantly in respect of clinical and treatment factors. Furthermore, the possible mechanisms responsible for the effects of topical treatment on radiation-induced dermatitis were investigated in vivo.

Results

The incidence of radiation-induced moist desquamation was 23% across 158 patients. Higher volume receiving 107% of prescribed dose within PTV (PTV-V107%; >28.6%) and volume receiving 110% of prescribed dose within treated volume (TV-V110%; > 5.13%), and no prophylactic topical therapy for irradiated skin, were associated with higher incidence of acute radiation dermatitis. The protective effect of prophylactic topical treatment was more pronounced in patients with TV-V110% > 5.13%. Furthermore, using irradiated mice, we demonstrated that topical steroid cream significantly attenuated irradiation-induced inflammation, causing a decrease in expression of inflammatory cytokines and TGF-beta 1.

Conclusion

TV-V110% > 5.13% may be an important predictor for radiation induced dermatitis. Prophylactic topical treatment for irradiated skin can significantly improve the tolerance of skin to adjuvant radiotherapy, especially for patients with higher TV-V110%.
Appendix
Available only for authorised users
Literature
1.
Gebski V, Lagleva M, Keech A, Simes J, Langlands AO: Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst. 2006, 98: 26-38. 10.1093/jnci/djj002.CrossRefPubMed
2.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002, 347: 1233-1241. 10.1056/NEJMoa022152.CrossRefPubMed
3.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y: Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366: 2087-2106.CrossRefPubMed
4.
Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005, 6: 557-565. 10.1016/S1470-2045(05)70251-5.CrossRefPubMed
5.
Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W, Fourquet A, Bartelink H, Ataman F, Gulyban A, Pierart M, Van Tienhoven G: EORTC Radiation Oncology & Breast Cancer Groups. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol. 2010, 49: 24-34. 10.3109/02841860903352959.CrossRefPubMed
6.
Chen MF, Tseng CJ, Tseng CC, Kuo YC, Yu CY, Chen WC: Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007, 67: 1438-1444. 10.1016/j.ijrobp.2006.11.005.CrossRefPubMed
7.
Ares C, Khan S, Macartain AM, Heuberger J, Goitein G, Gruber G, Lutters G, Hug EB, Bodis S, Lomax AJ: Postoperative Proton Radiotherapy for Localized and Locoregional Breast Cancer: Potential for Clinically Relevant Improvements?. Int J Radiat Oncol Biol Phys. 2010, 76: 685-97. 10.1016/j.ijrobp.2009.02.062.CrossRefPubMed
8.
Moon SH, Shin KH, Kim TH, Yoon M, Park S, Lee DH, Kim JW, Kim DW, Park SY, Cho KH: Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol. 2009, 90: 66-73. 10.1016/j.radonc.2008.09.027.CrossRefPubMed
9.
Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, Vu TT, Truong P, Ackerman I, Paszat L: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008, 26: 2085-92. 10.1200/JCO.2007.15.2488.CrossRefPubMed
10.
Morganti AG, Cilla S, Valentini V, Digesu' C, Macchia G, Deodato F, Ferrandina G, Cece MG, Cirocco M, Garganese G, Di Lullo L, Traficante D, Scarabeo F, Panunzi S, De Gaetano A, Sallustio G, Cellini N, Sofo L, Piermattei A, Scambia G: Phase I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients. Radiother Oncol. 2009, 90: 86-92. 10.1016/j.radonc.2008.10.017.CrossRefPubMed
11.
Schmuth M, Wimmer MA, Hofer S, Sztankay A, Weinlich G, Linder DM, Elias PM, Fritsch PO, Fritsch E: Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol. 2002, 146: 983-91. 10.1046/j.1365-2133.2002.04751.x.CrossRefPubMed
12.
Boström A, Lindman H, Swartling C, Berne B, Bergh J: Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol. 2001, 59: 257-65. 10.1016/S0167-8140(01)00327-9.CrossRefPubMed
13.
Pardo Masferrer J, Murcia Mejía M, Vidal Fernández M, Alvarado Astudillo A, Hernández Armenteros ML, Macías Hernández V, Soto Pérez R, Mirada Ferre A: Prophylaxis with a cream containing urea reduces the incidence and severity of radio-induced dermatitis. Clin Transl Oncol. 2010, 12: 43-8. 10.1007/s12094-010-0465-0.CrossRefPubMed
14.
Koh WJ, Stelzer KJ, Peterson LM, Staker BL, Ward WF, Russell KJ, Griffin TW: Effect of pentoxifylline on radiation-induced lung and skin toxicity in rats. Int J Radiat Oncol Biol Phys. 1995, 31: 71-7. 10.1016/0360-3016(94)E0307-6.CrossRefPubMed
15.
Wu CT, Chen WC, Lin PY, Liao SK, Chen MF: Androgen deprivation modulates the inflammatory response induced by irradiation. BMC Cancer. 2009, 9: 92-10.1186/1471-2407-9-92.CrossRefPubMedPubMedCentral
16.
Fleckenstein K, Gauter-Fleckenstein B, Jackson IL, Rabbani Z, Anscher M, Vujaskovic Z: Using biological markers to predict risk of radiation injury. Semin Radiat Oncol. 2007, 17: 89-98. 10.1016/j.semradonc.2006.11.004.CrossRefPubMed
17.
Halperin EC, Gaspar L, George S, Darr D, Pinnell S: A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys. 1993, 26: 413-416.PubMed
18.
Potera ME, Lookingbill DP, Stryker JA: Prophylaxis of radiation dermatitis with a topical cortisone cream. Radiology. 1982, 143: 775-777.CrossRefPubMed
19.
Williams MS, Burk M, Loprinzi CL, Hill M, Schomberg PJ, Nearhood K, O'Fallon JR, Laurie JA, Shanahan TG, Moore RL, Urias RE, Kuske RR, Engel RE, Eggleston WD: Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys. 1996, 36: 345-349.CrossRefPubMed
20.
Xiao Z, Su Y, Yang S, Yin L, Wang W, Yi Y, Fenton BM, Zhang L, Okunieff P: Protective effect of esculentoside A on radiation-induced dermatitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006, 65: 882-889. 10.1016/j.ijrobp.2006.01.031.CrossRefPubMed
21.
Chen MF, Keng PC, Lin PY, Yang CT, Liao SK, Chen WC: Caffeic acid phenethyl ester decreases acute pneumonitis after irradiation in vitro and in vivo. BMC Cancer. 2005, 5: 158-10.1186/1471-2407-5-158.CrossRefPubMedPubMedCentral
22.
Ostrau C, Hülsenbeck J, Herzog M, Schad A, Torzewski M, Lackner KJ, Fritz G: Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother Oncol. 2009, 92: 492-499. 10.1016/j.radonc.2009.06.020.CrossRefPubMed
23.
Rodemann HP, Blaese MA: Responses of normal cells to ionizing radiation. Semin Radiat Oncol. 2007, 17: 81-88. 10.1016/j.semradonc.2006.11.005.CrossRefPubMed
24.
Brush J, Lipnick SL, Phillips T, Sitko J, McDonald JT, McBride WH: Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol. 2007, 17: 121-130. 10.1016/j.semradonc.2006.11.008.CrossRefPubMed
25.
Anscher MS, Vujaskovic Z: Mechanisms and potential targets for prevention and treatment of normal tissue injury after radiation therapy. Semin Oncol. 2005, 32: S86-91. 10.1053/j.seminoncol.2005.03.015.CrossRefPubMed
26.
Linard C, Marquette C, Mathieu J, Pennequin A, Clarencon D, Mathe D: Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: effect of an NF-kappaB inhibitor. Int J Radiat Oncol Biol Phys. 2004, 58: 427-434. 10.1016/j.ijrobp.2003.09.039.CrossRefPubMed
27.
Martin M, Lefaix J, Delanian S: TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys. 2000, 47: 277-290. 10.1016/S0360-3016(00)00435-1.CrossRefPubMed
28.
Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL: Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1998, 41: 1029-1035. 10.1016/S0360-3016(98)00154-0.CrossRefPubMed
29.
Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, Finkelstein JN, Rubin P, Okunieff P: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 2002, 12: 26-33. 10.1053/srao.2002.31360.CrossRefPubMed
30.
Meeran SM, Akhtar S, Katiyar SK: Inhibition of UVB-induced skin tumor development by drinking green tea polyphenols is mediated through DNA repair and subsequent inhibition of inflammation. J Invest Dermatol. 2009, 129: 1258-1270. 10.1038/jid.2008.354.CrossRefPubMed
31.
Kobayashi H, Yazlovitskaya EM, Lin PC: Interleukin-32 positively regulates radiation-induced vascular inflammation. Int J Radiat Oncol Biol Phys. 2009, 74: 1573-1579. 10.1016/j.ijrobp.2009.04.017.CrossRefPubMedPubMedCentral
32.
Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R: Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007, 67: 3483-3491. 10.1158/0008-5472.CAN-06-3955.CrossRefPubMed
Metadata
Title
Predictive factors of radiation-induced skin toxicity in breast cancer patients
Authors
Miao-Fen Chen
Wen-Cheng Chen
Chia-Hsuan Lai
Chao-hsiung Hung
Kuo-Chi Liu
Yin-Hsuan Cheng
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-508

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study

Research article

Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens

Research article

Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11

Research article

Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures

Research article

Evaluation of mammographic density patterns: reproducibility and concordance among scales

Study protocol

Distress and quality of life after autologous stem cell transplantation: a randomized clinical trial to evaluate the outcome of a web-based stepped care intervention

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits